Uyghur Forced Labor Prevention Act Entity List
The Uyghur Forced Labor Prevention Act Entity List has been updated, potentially adding entities to the list of those prohibited from importing goods into the U.S. due to forced labor concerns.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 31, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that import or use materials from entities on the UFLPA Entity List. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate review recommended; no specific deadline provided in the change text.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The Uyghur Forced Labor Prevention Act Entity List has been updated, potentially adding new entities. This affects supply chains that may involve inputs from Xinjiang or entities on the list.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that import or use materials from entities on the UFLPA Entity List.
What you must do
Review the updated Entity List to determine if any current or potential suppliers are newly listed, and assess supply chain exposure.
Deadline
Immediate review recommended; no specific deadline provided in the change text.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues - pharmaceuticalcommerce.com
- Final Debarment Order: Ricardo Andres Acuna
- Final Debarment Order: Angela Anatilde Baquero
- Guidance: Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts
- Guidance: Assessing Adhesion with Transdermal and Topical Delivery Systems for Abbreviated New Drug Applications